Mass. insurers cover fewer GLP-1 users

Private health insurers in Massachusetts significantly reduced coverage for GLP-1 medications used for obesity treatment earlier this year, resulting in over 100,000 fewer residents having their prescriptions covered. The discontinuation followed insurers citing financial losses due to high drug costs, with coverage largely ending for individuals without diabetes or related conditions. Although some public insurers still provide coverage, many residents face high out-of-pocket costs, raising concerns about healthcare inequalities and the long-term impact on health outcomes.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل